Munich, Germany

Hendrik Gille

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 6.2

ph-index = 2

Forward Citations = 26(Granted Patents)


Location History:

  • Berlin, DE (2020)
  • Munich, DE (2015 - 2021)

Company Filing History:


Years Active: 2015-2021

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Hendrik Gille

Introduction

Hendrik Gille, based in Munich, Germany, is an accomplished inventor with a focus on biotechnology. With a total of six patents to his name, Gille has made significant advancements in the field of pharmaceuticals, particularly in treatments related to angiogenesis. His innovative work demonstrates a strong dedication to enhancing medical interventions and therapeutic applications.

Latest Patents

Hendrik Gille's latest patents revolve around "Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)." These patents provide detailed disclosures of hNGAL muteins that effectively bind Ang-2 and can be utilized across various pharmaceutical applications. The inventions are poised to inhibit or reduce angiogenesis, thereby offering potential therapeutic and diagnostic uses. The associated methods relate to the creation of such muteins and the advancement of nucleic acid molecules that facilitate their generation.

Career Highlights

Throughout his career, Hendrik Gille has worked with leading companies, including Pieris Pharmaceuticals GmbH and Pieris AG. His contributions at these institutions have been instrumental in shaping innovative pharmaceutical solutions, particularly for conditions linked to angiogenesis.

Collaborations

In his professional journey, Gille has collaborated with notable colleagues such as Laurent Audoly and Stefan Trentmann. These partnerships underscore the collaborative spirit within scientific research, contributing to the development of groundbreaking inventions that may enhance healthcare outcomes.

Conclusion

Hendrik Gille exemplifies the spirit of innovation in the biotechnology sector. His patents, centered around hNGAL muteins and their potential applications, highlight his commitment to improving therapeutic strategies. Through his work and collaborations, Gille continues to be a pivotal figure in the quest for advanced medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…